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Long-Term Vascular Healing in Response to
Sirolimus- and Paclitaxel-Eluting Stents
An Optical Coherence Tomography Study
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eter Jüni, MD,‡ Stephan Windecker, MD*
ern and Biel, Switzerland; and Rotterdam, the Netherlands
Objectives This study sought to assess stent strut coverage, malapposition, protrusion, and coro-
nary evaginations as markers of healing 5 years after implantation of sirolimus-eluting stents (SES)
and paclitaxel-eluting stents (PES), by optical coherence tomography (OCT).
Background Early-generation drug-eluting stents have been shown to delay vascular healing.
Methods A total of 88 event-free patients with 1 randomly selected lesion were suitable for ﬁnal
OCT analysis 5 years after drug-eluting stent implantation. The analytical approach was based on a
hierarchical Bayesian random-effects model.
Results OCT analysis was performed at 5 years in 41 SES lesions with 6,380 struts, and in 47 PES
lesions with 6,782 struts. A total of 196 struts were uncovered in SES (1.5%) compared with 185
struts in PES lesions (1.0%, 95% credibility interval [CrI]: 0.5 to 1.6; p  0.32). Malapposed struts
were present in 1.2% of SES compared with 0.7% of PES struts (0.7%, 95% CrI: 0.03 to 1.6; p  0.23).
Protruding struts were more frequent among SES (n  114; 0.8%) than PES lesions (n  24; 0.1%,
95% CrI: 0.3 to 1.3; p  0.01). Coronary evaginations were more common among SES- than PES-
treated lesions (17 vs. 7 per 100 cross sections, p  0.003). During extended clinical follow-up, 2
patients suffered from very late stent thrombosis showing a high degree of malapposition, protru-
sion, and coronary evaginations at the time of OCT investigation.
Conclusions Early-generation drug-eluting stents show a similar degree of strut coverage and
malapposition at 5 years of follow-up. Despite an overall low degree of uncovered and malapposed
struts in event-free patients, some lesions show a clustering of these characteristics, indicating a het-
erogeneous healing response, which may be the source for very late adverse events. (J Am Coll
Cardiol Intv 2012;5:946–57) © 2012 by the American College of Cardiology Foundation
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947Although early-generation drug-eluting stents (DES)
have a similar safety profile as bare-metal stents do, the
phenomenon of late stent thrombosis (ST) emerged as a
distinct entity complicating their use (1,2). Experimental
studies and autopsy reports identified delayed endotheli-
alization, chronic inflammation, and neoatherosclerosis
as morphological features differentiating early generation
DES from bare-metal stents (3– 6). Incomplete endothe-
lial coverage was identified as the most important pre-
dictor of late ST in an autopsy study with a risk
continuum that increased with the numbers of uncovered
struts (7). In addition, a high incidence of late acquired
stent malapposition and positive vessel remodeling cor-
relating with the extent of inflammatory cell infiltration
was observed in intravascular ultrasound studies of pa-
tients suffering from late ST (8). Recently, differences in
the vascular healing response as well as differential
mechanisms leading to late ST have been reported for
lesions treated with either sirolimus-eluting stents (SES)
or paclitaxel-eluting stents (PES) (9).
Optical coherence tomography (OCT) allows for high-
resolution intracoronary imaging and has been validated for
assessment of stent strut coverage and apposition with an
accuracy resembling that of histological examinations
(10,11). Using OCT, early generation DES have been
associated with a higher frequency of uncovered, malap-
posed, and protruding struts than bare-metal stents have
(12,13). The use of this technology among event-free
patients may contribute to the understanding of mecha-
nisms underlying the continuous risk of late ST, may
potentially identify patients at risk, and may offer guidance
in the need for long-term dual antiplatelet therapy. Most
OCT studies to date assessed strut coverage and apposition
within the first year of DES implantation (12,14–17).
However, autopsy studies indicate that arterial healing after
DES implantation is delayed, warranting longer-term im-
aging follow-up. The present study provides quantitative
OCT findings at 5 years after DES implantation comple-
mented by geographic maps integrating the pattern of strut
coverage, apposition, and protrusion and describes differ-
ences in the vascular healing response between SES and
PES.
Methods
Patient population. The design and results of SIRTAX
Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting
tent for Coronary Revascularization) and SIRTAX LATE
Sirolimus-Eluting Stent Compared With Paclitaxel-
luting Stent for Coronary Revascularization-Late) have
een reported previously (18,19). For the purpose of the
resent study, all consecutive patients undergoing angio-
raphic follow-up at 5 years during the period between
ecember 2008 and July 2009 (n  145) were eligible for aCT imaging (Fig. 1). The inclusion period commenced
ith the availability of the OCT console at Bern University
ospital in December 2008. The present study was limited
o 1 lesion to ensure optimal image quality and minimize
atient discomfort. Among patients scheduled for repeat
ngiography between December 2008 and July 2009, who
ad more than 1 study lesion (n  19), all lesions were
randomly allocated a numerical code of 1, 2, or 3 by an
independent statistician. OCT was routinely performed in
the lesion with the lowest number. In 4 patients with
multiple lesions, OCT was technically not feasible. In none
of these patients, the second or third lesion underwent
OCT to respect the random selection. Thus, in 15 of 88
patients suitable for final analysis, lesion selection was
random. The study complied with the Declaration of
Helsinki regarding investigation in humans and was ap-
proved by the institutional ethics committees at Bern
University Hospital, Switzerland. All patients provided
written informed consent.
OCT imaging and analysis. OCT was performed with a time
omain M2 system (Lightlab
maging, Westford, Massachu-
etts) using a pullback speed of 2
m/s and the nonocclusive
ushing technique. After the di-
gnostic angiography and admin-
stration of 5,000 IU unfractionated
eparin, the ImageWire (Lightlab
maging) was carefully advanced
istal to the study lesion. Fol-
owing administration of 200 g
f nitroglycerin intracoronary,
he target vessel was flushed via
he guiding catheter with non-
onic, isosmolar contrast liquid (Iodixanol 320, Visipaque,
E Healthcare, Cork, Ireland) using a power injector with
ush rates between 3 and 4 ml/s. OCT pullbacks were
ssessed offline using a proprietary software (Lightlab Im-
ging). Lesions were analyzed performing OCT cross sec-
ions at 1-mm intervals and assessed for strut coverage,
pposition, and protrusion by a single analyst blinded. All
rames were reviewed by a second analyst who in case of
isagreement consulted with a third referee, and final
ecision was based on consensus. Pullbacks were excluded in
ase 30% of the total stent length was not analyzable.
rames were considered not analyzable when more than
ne-quarter of the circumference was not visible due to
nsufficient flush or out of zoom. A strut was defined as a
ignal-intense bright spot with a typical dorsal shadowing.
hickness of strut coverage was measured as the distance
etween the endoluminal side of the strut in the midpoint of
ts long axis and the intersection of the lumen contour with
he straight line between the endoluminal side of the strut
Abbreviations
and Acronyms
CrI  credibility interval
DES  drug-eluting stent(s)
OCT  optical coherence
tomography
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosisnd the gravitational center of the vessel. Struts were
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948Figure 2. Qualitative and Quantitative Assessment of Stent Strut Coverage, Protrusion, and Malapposition
A cross section illustrating all 3 categories is shown on the left. The strut at position 1 is apposed to the vessel wall and covered by a layer (130 m), whereas
the strut in position 2 is uncovered but apposed to the vessel. The strut at position 3 was classiﬁed as protruding because the measured protrusion into the
lumen relative to an imaginary lumen line (yellow) was 160 m. Two malapposed struts are shown at position 4 with a separation of 160 m from theFigure 1. Flow Chart Showing Study Design and Patient Flow
OCT  optical coherence tomography; PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s).lumen and with absence of tissue between strut and lumen.
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949considered uncovered in case of a partial or complete
absence of tissue coverage. Strut protrusion was defined as
strut extension into the lumen for more than 160 m but
ith no obvious separation from the vessel wall (Fig. 2).
pposition was assessed by measuring the distance between
he center of the endoluminal strut surface and the inter-
ection between lumen contour and the line connecting the
enter of the endoluminal strut side and the gravitational
enter of the vessel. Strut malapposition was defined as a
istance 160 m based on the consensus derived from the
strut thickness of SES (153 m) and PES (148 m) plus
he minimal axial resolution of OCT (10 m). This
consensus allowed a blinded assessment. Geographic maps
were created displaying struts using color codes for strut
characteristics, including strut coverage, apposition, and
protrusion. The resultant map represented the stented vessel
cut longitudinally along the reference angle 0° (correspond-
ing to the 12 o’clock position in the respective OCT cross
section) and spread out on an area (Fig. 3A).
Evaginations were suspected whenever the luminal vessel
contour extended in a pouchlike fashion beyond the line
connecting all stent struts (stent contour). Under these
circumstances, the maximal radial distance between the
circular line connecting all struts and the luminal vessel wall
was evaluated using the thickness ruler function. When the
maximal depth exceeded 160 m (similar cutoff as for the
resence of malapposition), we considered the outward
ulging as evagination (Fig. 4). By definition, the evagina-
ion is limited laterally by stent struts. In addition to the
aximal depth of the evagination, the interstrut evagination
rea was assessed. The interstrut evagination area was
efined as the area limited by the stent contour luminally
nd the lumen contour abluminally.
Statistical analysis. We used a Bayesian hierarchical random-
ffects model based on Markov chain Monte Carlo simulation
ethods with vague priors to estimate differences between
ES and PES (18). For analyses at the cross-section and strut
evel, the model included random-effects at the level of pa-
ients, fully accounting for the correlation of characteristics
f cross-sectional areas or struts within patients and implic-
tly assigning analytical weights to each lesion depending on
he number of cross sections or on the number of struts
bserved per lesion. For continuous outcomes, we assumed
log normal distribution; for counts, we used a Poisson
istribution; and we used appropriate transformations to
erive arithmetic means and rates, respectively. Differences
n the percentage of lesions with any struts with unfavorable
utcome, with at least 5%, and with at least 10% of struts
ith unfavorable outcome were calculated using a Bayesian
ierarchical random-effects model assuming a Bernoulli
istribution. For all other analyses at the lesion level, we
sed conventional linear and Poisson regression models,
epending on the nature of the outcome (continuous or
ounts). We derived 95% credibility intervals (CrI) from the.5th and 97.5th percentiles of the posterior distribution,
lso calculating 2-sided p values from the posterior distri-
ution. Statistical analyses were performed using Win-
UGS (version 1.4.3, Imperial College and Medical Re-
earch Council, London, United Kingdom) and Stata
version 11.0, StataCorp, College Station, Texas).
esults
Patients. The flow of patients included into the OCT study
5 years after DES implantation is shown in Figure 1. Of 95
patients undergoing OCT at 5.3 years (interquartile range:
Figure 3. Geographic Stent Strut Maps
(A) The concept of the creation of geographic stent strut maps is illus-
trated. Lesions are presented as areas assuming a cylindrical geometry of
the stent. Struts are color coded according to coverage, apposition, and
protrusion. The x axis represents the length of the stent (mm), whereas the
y axis indicates the position of the strut in the individual cross section
ranging from 0° to 360°.
Continued on the next page5.1 to 5.5 years), 46 patients had been treated with SES and
tent o
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95049 patients with PES. Five SES patients and 2 PES patients
were excluded (Fig. 1), resulting in 41 SES and 47 PES
patients included into the final analysis. Baseline clinical and
Figure 3. Continued
(B) Strut coverage is presented using green for covered struts and red for un
green; protruding struts in yellow; and malapposed struts in red. The x-axis r
of the strut in the individual cross section ranging from 0° to 360°. Zones of s
Figure 4. Coronary Evaginations
(A) Illustration of a cross-section showing 3 coronary evaginations. (B) The qu
relates to evagination areas; d1 to d3 relates to evagination depth.angiographic characteristics among patients undergoing OCT
at 5 years were well balanced for both groups (Table 1).
Baseline angiographic and procedural characteristics at the
d struts. (C) Strut apposition is presented. Apposed struts are shown in
nts the length of the stent (mm), whereas the y-axis indicates the position
verlap are marked with blue lines. Abbreviations as in Figure 1.
ive assessment of coronary evagination depth and area is shown. A1 to A3covere
epreseantitat
v
L
w
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951time of DES implantation were similar for both groups,
including lesion length; vessel size; and the number, diam-
eter, and length of implanted stents (Table 2). Angiographic
follow-up at 5 years showed similar results in terms of
minimal lumen diameter, percentage of diameter stenosis,
late loss, and restenosis for both stent types (Table 3).
OCT data. Quantitative analysis of luminal, stent, and neo-
intimal volume and percentage of volume obstruction
showed no differences between SES and PES at 5 years of
follow-up (Table 4).
Results of strut-level and lesion-level OCT analyses
stratified according to stent type are presented in Table 5. A
total of 6,380 struts in 41 SES lesions and 6,782 struts in 46
PES lesions were analyzed. Uncovered struts were observed
among 1.5% (95% CrI: 0.8% to 2.6%) of all SES struts
compared with 1.0% (95% CrI: 0.5% to 1.7%) of all PES
struts (weighted difference: 0.5%, 95% CrI: 0.5% to 1.6%;
p  0.32). Lesion-level analysis showed no difference in the
proportion of lesions with 5% (10.7% vs. 7.2%, 95% CrI:
9.6% to 18.7%; p  0.60) as well as 10% uncovered struts
(2.4% vs. PES 2.0%, 95% CrI: 4.8% to 7.9%; p  0.81)
between SES and PES (Table 5, Fig. 5A). A geographic
map with the spatial distribution of uncovered and covered
struts is provided in Figure 3B. A high density of uncovered
struts is noted in Lesions #10 and #13 of SES-treated
patients and Lesion #35 of PES-treated patients.
Overall, malapposed struts were observed in 1.2% (95%
Table 1. Baseline Clinical Characteristics
SES
(n  41)
PES
(n  47) p Value
Age 60 yrs 16 (39) 28 (59.3) 0.10
Male 34 (82.9) 36 (76.6) 0.46
Diabetes mellitus 8 (19.5) 8 (17.0) 0.76
Insulin dependence 2 (4.9) 3 (6.4) 0.76
Hypertension 21 (51.2) 30 (63.8) 0.23
Hyperlipidemia 25 (61.0) 25 (53.2) 0.46
Current smoking 19 (46.3) 16 (34.0) 0.24
Previous myocardial infarction 11 (26.8) 14 (29.89) 0.76
Stable angina pectoris 15 (36.6) 21 (44.7) 0.45
Acute coronary syndromes
Unstable angina 4 (9.8) 1 (2.1) 0.45
Non–STEMI 9 (22.0) 11 (23.4)
STEMI 13 (31.7) 14 (29.8)
Multivessel disease 30 (73.8) 30 (63.8) 0.35
Lesion(s) per patient
1 35 (85.4) 37 (78.7) 0.71
2 5 (12.2) 8 (17.0)
3 1 (2.4) 2 (4.3)
Left ventricular ejection fraction, % 56.7 58.6 0.40
Values are n (%) or %.
PES paclitaxel-eluting stent(s); SES sirolimus-eluting stent(s); STEMI ST-segment eleva-
tion myocardial infarction.CrI: 0.6% to 2.2%) of all SES struts compared with 0.7%(95% CrI: 0.3% to 1.3%) of all PES struts (weighted
difference: 0.5%, 95% CrI: 0.03 to 1.6; p 0.23). The mean
area of stent malapposition showed no difference between
SES and PES (SES: 0.70 mm2 [95% CrI: 0.5% to 0.96%]
s. PES: 0.68 mm2 [95% CrI: 0.49 to 0.94]; p  0.88).
esion-level analysis of malapposition showed more lesions
ith 5% (24.0% vs. 5.7%, weighted difference: 17.5%,
5% CrI: 1.9% to 39.3%; p  0.03), as well as 10%
Table 2. Baseline Characteristics of Lesions Undergoing OCT Analysis
SES PES p Value
Lesions, n 41 47
Target lesion coronary artery
Left main 1 (2.4) 1 (2.1) 0.31
Left anterior descending 17 (41.5) 25 (53.2)
Left circumﬂex 13 (31.7) 7 (14.9)
Right 10 (24.4) 14 (29.8)
ACC-AHA lesion class
A 4 (9.8) 9 (19.1) 0.53
B1 17 (41.5) 20 (42.6)
B2 13 (31.7) 10 (21.3)
C 7 (17.1) 8 (17.0)
Angiographic measurements
Lesion length 16.95 7.84 15.70 7.23 0.44
Reference vessel diameter 2.87 0.40 2.89 0.41 0.82
Minimal lumen diameter 0.40 0.37 0.48 0.38 0.36
Stenosis, % lumen diameter 85.95 12.6 83.38 13.0 0.35
Pre-procedure TIMI ﬂow grade
0 13 (31.7) 8 (17.0) 0.44
1 2 (4.9) 2 (4.3)
2 3 (7.3) 4 (8.5)
3 23 (56.1) 33 (70.2)
Post-procedure TIMI ﬂow grade 1.0
0 0 (0) 0 (0)
1 0 (0) 0 (0)
2 1 (2.4) 1 (2.1)
3 40 (97.6) 46 (97.9)
Thrombus present 13 (32.5) 16 (34.0) 0.88
Procedures
Study stents per lesion 1.17 0.4 1.15 0.4 0.80
Stent diameter, mm 2.88 0.39 2.96 0.37 0.34
Total stent length per lesion, mm 20.59 9.05 18.47 7.67 0.24
Maximal pressure, atm 15.32 3.6 14.43 3.2 0.22
Direct stenting 0.22 0.4 0.30 0.5 0.41
Angiographic results
Reference vessel diameter, mm 2.89 0.50 2.89 0.44 1.00
Final minimal lumen diameter, mm
In-stent 2.68 0.41 2.75 0.41 0.42
In-segment 2.60 0.43 2.75 0.52 0.25
Final stenosis, % of lumen diameter
In-stent 7.73 4.5 5.55 4.3 0.03
In-segment 9.80 6.4 6.12 6.6 0.04
Acute gain, mm
In-stent 2.28 0.50 2.28 0.51 1.00
In-segment 2.22 0.49 2.32 0.66 0.54
Values are n, n (%), or mean SD.
ACC  American College of Cardiology; AHA  American Heart Association; OCT  optical
coherence tomography; TIMI Thrombolysis In Myocardial Infarction; other abbreviations as inTable 1.
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952malapposed struts among SES- than PES-treated patients
(5.4% vs. 0.4%, weighted difference: 4.6, 95% CrI: 0.0% to
16.3%; p  0.05) (Table 5, Fig. 5B), indicating an accu-
ulation of malapposed struts in some SES lesions. Geo-
raphic stent strut maps are confirmatory in this regard and
llow a visual assessment of the distribution of malapposed
truts within a lesion.
Table 3. Angiographic Follow-Up Results at 5 Years
SES
Lesions, n 41
Reference vessel diameter, mm 2.83 0.44
Minimal lumen diameter, mm
In-stent 2.39 0.71
In-segment 2.31 0.72
% diameter stenosis
In-stent 15.82 17.2
In-segment 18.23 17.9
Late loss, mm
In-stent 0.28 0.43
In-segment 0.26 0.39
Binary restenosis
In-stent 2 (4.9)
In-segment 2 (4.9)
Values are n,mean SD, or n (%). Rowpercentages are predicted prob
are predicted values derived from mixed maximum likelihood regre
continuous and mixed maximum logistic regression models for binary
relate to the difference between 2 stent types.
CrI credibility intervals; other abbreviations as in Tables 1 and 2.
Table 4. Results of OCT Analysis—Continuous Outco
SES (95% CrI)
Analysis at lesion level
Lesions analyzed, n 41
Cross sections analyzed per lesion 19.1 (17.9 to 20.5)
Struts analyzed per lesion 155.6 (151.8 to 159
Minimal luminal area, mm2 4.66 (3.95 to 5.38)
Minimal stent area, mm2 5.37 (4.81 to 5.94)
Percentage of volume obstruction 12.2 (8.58 to 14.9)
Analysis at cross-section level
Cross sections analyzed, n 785
Struts per cross section 7.98 (7.52 to 8.45)
Luminal area, mm2 5.67 (5.05 to 6.32)
Stent area, mm2 6.50 (3.62 to 7.17)
Neointimal thickness, mm 0.11 (0.09 to 0.12)
Neointimal area, mm2 0.97 (0.86 to 1.10)
Mean area ISA, mm2 0.70 (0.50 to 0.96)
Mean malapposition distance, mm 0.27 (0.24 to 0.31)
Number of evaginations 0.17 (0.10 to 0.26)
Mean evagination area, mm2 0.20 (0.17 to 0.24)
Mean evagination depth, mm 0.25 (0.24 to 0.28)
Values are n or mean/% (95% CrI).ISA incomplete stent apposition; other abbreviations as in Tables 1 to 3.Protruding struts were more frequent among SES (0.8%,
95% CrI: 0.4% to 1.4%) than PES in the strut-level analysis
(0.1%, 95% CrI: 0.0% to 0.3%; weighted difference: 0.7%,
95% CrI: 0.3% to 1.3%; p 0.01). Similarly, the number of
lesions with 5% (3.7% vs. 0.3%, weighted difference:
3.1%, 95% CrI: 0.2% to 13%; p  0.07), as well as 10%
protruding struts (0.6% vs. 0.0%, weighted difference: 0.5%,
ions Undergoing OCT Analysis
PES Difference (95% CrI) p Value
47
6 0.38 0.03 (0.21 to 0.14) 0.69
5 0.76 0.06 (0.28 to 0.16) 0.57
3 0.77 0.02 (0.24 to 0.20) 0.86
8 18.4 1.04 (4.22 to 6.31) 0.70
1 19.2 0.19 (5.67 to 5.30) 0.95
8 0.46 0.00 (0.13 to 0.13) 1.00
8 0.42 0.02 (0.14 to 0.10) 0.72
2 (4.3) 0.62 (8.52 to 9.76) 0.89
3 (6.4) 1.50 (12.6 to 9.56) 0.79
derived frommixedmaximum logistic regressionmodels.Mean SD
odels. Mixed maximum likelihood regression models were used for
es to derive the differences between women and men. The p values
PES (95% CrI) Difference (95% CI) p Value
47
16.8 (15.7 to 18.0) 1.13 (1.03 to 1.26) 0.01
144.3 (140.9 to 147.8) 1.08 (1.04 to 1.11) 0.001
5.08 (4.49 to 5.67) 0.42 (0.48 to 1.32) 0.36
6.22 (5.62 to 6.81) 0.84 (0.02 to 1.66) 0.04
13.7 (11.6 to 15.8) 1.53 (2.43 to 5.48) 0.45
790
8.36 (7.90 to 8.82) 0.38 (1.00 to 0.28) 0.25
6.33 (5.72 to 7.04) 0.66 (1.62 to 0.19) 0.15
7.35 (6.72 to 12.3) 0.85 (8.83 to 0.14) 0.09
0.11 (0.10 to 0.13) 0.01 (0.03 to 0.02) 0.64
1.03 (0.91 to 1.16) 0.06 (0.24 to 0.12) 0.46
0.68 (0.49 to 0.94) 0.02 (0.31 to 0.34) 0.88
0.29 (0.26 to 0.34) 0.02 (0.07 to 0.03) 0.47
0.07 (0.04 to 0.10) 0.10 (0.03 to 0.20) 0.003
0.23 (0.19 to 0.28) 0.03 (0.08 to 0.02) 0.24
0.24 (0.22 to 0.27) 0.01 (0.02 to 0.04) 0.47of Les
2.8
2.4
2.3
14.7
18.4
0.2
0.2
abilities
ssion m
outcommes
.5)
and strut malapposition (B). Abbreviations as in Figure 1.
Abbreviations as in Tables 1 to 3.
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95395% CrI: 0.0% to 16.3%; p  0.12) tended to be higher
among SES than PES (Table 5) in the lesion-level analysis.
In a total of 5 SES lesions and 2 PES lesions, overlapping
stents were observed. The overlapping zones were delin-
eated in the strut maps in Figures 3B and 3C. Visual
inspection shows that neither uncovered nor malapposed
struts were more frequent in overlapping zones.
The number of coronary evaginations was higher among
SES- than PES-treated lesions (0.17 vs. 0.07 per cross sec-
tions; p  0.003), with no difference in mean area and depth
of individual evaginations. A geographic map showing the
spatial distribution of apposed, malapposed, and protruding
struts is provided in Figure 3C. A high density of strut
malapposition or protrusion (20%) is visible in Lesions #7,
#13, #21, and #40 of SES-treated patients. Of these 4 SES
patients, 2 (#7 and #40) suffered very late ST at 6 months and
1 year after acquisition of OCT imaging, respectively.
Discussion
The present OCT analysis performed among event-free
patients 5 years after the intervention focused on the
vascular healing response to early-generation SES and PES
implanted in the framework of an all-comers randomized
trial and has the following principal findings:
1. Neointimal thickness and volume are low and of
similar magnitude for SES and PES at 5 years.
2. Strut-level analysis shows an overall low frequency of
uncovered, malapposed, or protruding struts at 5 years.
3. Geographic maps identified a few patients with a high
degree of uncovered, malapposed, or protruding struts
suggesting a heterogeneous healing pattern 5 years
PES (95% CrI) Difference (95% CrI) p Value
6,782
1.0 (0.5 to 1.7) 0.5 (0.5 to 1.6) 0.32
0.1 (0.0 to 0.3) 0.7 (0.3 to 1.3) 0.01
0.7 (0.3 to 1.3) 0.5 (0.3 to 1.6) 0.23
2.0 (0.2 to 7.6) 0.4 (4.8 to 7.9) 0.81
7.2 (1.7 to 20.6) 3.1 (9.6 to 18.7) 0.60
0.0 (0.0 to 0.8) 0.5 (0.3 to 5.0) 0.12
0.3 (0.0 to 3.6) 3.1 (0.2 to 13.0) 0.07
0.4 (0.0 to 6.9) 4.6 (0.0 to 16.3) 0.05
5.7 (1.3 to 15.9) 17.5 (1.9 to 39.3) 0.03Figure 5. Frequency Distribution of Uncovered and Malapposed Struts
Cumulative distribution of the proportion of uncovered struts (A)Table 5. Results of OCT Analysis—Counts
SES (95% CrI)
Analysis at strut level
Struts analyzed, n 6,380
Uncovered struts, % 1.5 (0.8 to 2.6)
Protruding struts, % 0.8 (0.4 to 1.4)
Malapposed struts, % 1.2 (0.6 to 2.2)
Analysis at lesion level
Uncovered struts, lesions with
At least 10% uncovered struts 2.4 (0.3 to 10.8)
At least 5% uncovered struts 10.7 (2.9 to 26.7)
Protruding struts, lesions with
At least 10% protruding struts 0.6 (0.0 to 5.0)
At least 5% protruding struts 3.7 (0.6 to 13.8)
Malapposed struts, lesions with
At least 10% malapposed struts 5.4 (1.0 to 17.6)
At least 5% malapposed struts 24.0 (8.9 to 45.2)
Values are n, mean/% (95% CrI).after early-generation DES implantation.
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9544. Lesion-level analysis and geographic maps demon-
strate a clustering of malapposition and protrusion in
SES- versus PES-treated lesions, and coronary evagi-
nations were more frequently observed in SES, sug-
gesting a potential difference in the healing response
of the 2 devices at 5 years of follow-up.
Neointimal thickness, neointimal volume, and percentage
of volume obstruction were low and of similar magnitude
for SES and PES at 5 years. Although these data were
obtained in selected, nonrandomized patients, the OCT
findings of the present study confirm similar observations in
a recent autopsy study as well as an angiographic study (19)
with late follow-up indicating the absence of significant
differences in neointimal hyperplasia between SES and PES
during long-term follow-up (9). Figure 6 illustrates the
spectrum of neointimal phenotypes encountered 5 years
after implantation of SES and PES.
Strut coverage. A number of OCT studies have investi-
gated strut coverage among SES-treated lesions at various
time points, but only very few are available for PES-treated
lesions. The rate of uncovered struts in SES-treated lesions
amounted to 15% at 3 months (20), 11% at 6 months (15),
and 2.1% at 9 months (16). Although a direct comparison
between the present study and previous reports is limited
due to patient and lesion heterogeneity as well as differences
in the analytical approach, there is a consistent increase in
strut coverage, which is most pronounced during the first
year but continues to accrue over time, resulting in a rate of
uncovered struts of only 1% to 2% at 5 years. This
observation is corroborated in a recent autopsy study report-
Figure 6. Spectrum of Neointimal Phenotypes Observed at 5 Years After Im
(A1 to A3) SES. (B1 to B3) PES. Panels A1 and B1 show absence of coverage,
observed. In A3 and B3, a more pronounced coverage is present with a maxim
Figure 1.ing a decrease in the incidence of uncovered struts over time
particularly among DES implanted in on-label indications
(9). The same study also observed no difference in the
proportion of uncovered struts between SES and PES in
analogy to our OCT findings. To date, only 1 autopsy study
showed a correlation between uncovered struts and the risk
of stent thrombosis, suggesting delayed endothelialization
and incomplete healing as potential mechanisms of late ST
after DES implantation. Specifically, the odds for late ST
were 9-fold increased among stents with more than 30% of
uncovered struts per cross section compared with stents in
control subjects (7). This observation has not been validated
among living DES-treated patients using intracoronary
imaging so far. Moreover, most available OCT studies only
addressed overall strut coverage using strut-level (cross-
sectional) analyses without accounting for a potential clus-
tering of uncovered struts within lesions (patients). To
address this limitation, we performed both a strut-level and
lesion-level analysis and provide geographic maps of strut
coverage for individual lesions. Whereas overall strut cov-
erage was found to be nearly complete, lesion-level analysis
indicated that 10.7% of SES- and 7.2% of PES-treated
lesions had at least 5% uncovered struts. Accordingly,
clustering (10%) with a higher density of uncovered struts
was limited to few lesion numbers (SES #10, SES #13, PES
#35, and PES #40) (Fig. 5A), whereas most geographic
maps revealed only isolated single uncovered struts, suggest-
ing an individual healing response after DES implantation.
Strut apposition. Stent malapposition 5 years after DES
mplantation may be related to persistent or late acquired
ation of SES and PES
as in A2 and B2, minimal coverage with a thickness 100 m can be
ickness of 820 m in SES (A3) and 600 m in PES (B3). Abbreviations as inplant
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955malapposition after resolution of thrombus or due to a
dynamic process with positive vessel remodeling over time
related to DES-induced inflammation and toxicity (8).
The assessment of malapposition in this study has to be
interpreted in the light of 1 important limitation: In the
absence of a baseline investigation, it is not possible to
differentiate whether malapposed struts at 5 years were
present at the time of the index procedure (persistent) or
whether malapposition developed during follow-up (late
acquired).
Overall, malapposed struts were rare and occurred with
similar frequency among SES- and PES-treated lesions in the
strut-level analysis. However, lesion-level analysis of strut
Table 6. VLST Cases
Ca
Baseline ﬁndings
Age, yrs
cvRF Smoking
Arterial hypertension
Family history
Indication for PCI at baseline STEMI
Target lesion Proximal LAD
Treatment at baseline Rescue PCI following
Implantation of a sin
TIMI ﬂow grade before
TIMI ﬂow grade after
LVEF, %
Maximum CK, U/l 5,6
DAPT duration, yrs
OCT ﬁndings at 5 yrs
Uncovered struts, %
Malapposed struts,%
Protruding struts, %
Coronary evagination
Depth, mm
Area, mm2
Per cross section, n
Map # #
Findings at time point of VLST
Time point of VLST, yrs after index
procedure
Time between OCT and VLST, yrs
Antiplatelet therapy before VLST Only aspirin
Clinical presentation Anterior STEMI
OCT performed No
Interventional treatment Thrombus aspiration
(zotarolimus-eluti
TIMI ﬂow grade before
TIMI ﬂow grade after
LVEF, %
Maximal CK, U/l 9
CK  creatine kinase; cvRF  cardiovascular risk factors; DAPT  d
ventricular ejection function; PCI  percutaneous coronary interveabbreviations as in Tables 1 and 2.malapposition revealed clustering, with a higher density of
malapposed struts among SES- than PES-treated lesions.
Protruding struts according to our definition did protrude
at least 160 m into the lumen and were always in contact
ith the vessel wall. Protruding struts may represent a stage
f healed, formerly malapposed struts related to incomplete
tent apposition at the time of DES implantation or may be
he result of an outward remodeling of the vessel wall giving
he appearance of coronary evaginations between the struts.
lthough protruding struts were rare overall, they occurred
ore frequently among SES- than PES-treated lesions.
aken together with the more pronounced clustering of
alapposed struts in SES lesions, this observation suggests
Case #2
56
ity
Smoking
Family history
STEMI
Proximal RCA
thrombolysis
S 3.5  8 mm
Primary PCI
Implantation of 2 SES 2.75  13
and 2.75  8 mm without overlap
0
3
50
2,922
1
2.9
23
8
0.42
0.37
1.75
#7
5.5
0.5
Only aspirin
Inferior STEMI
Yes (Fig. 7)
tent implantation
t, 3.5  30 mm)
Thrombus aspiration and balloon dilation
without stent implantation
2
3
50
Troponin T 0.2 ng/ml
iplatelet therapy; LAD  left anterior descending artery; LVEF  left
CA  right coronary artery; VLST  very late stent thrombosis; otherse #1
28
obes
failed
gle SE
0
3
50
40
1
1.4
31
35
0.62
0.58
1.75
40
6
1
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956a differential healing response following implantation of
SES and PES during long-term follow-up. A differential
healing response of the 2 stent types has also been reported
in a recent autopsy study. Histologically, an increased
inflammatory response resulting in positive remodeling and
malapposition has been associated with SES, whereas an
excessive para-strut fibrin deposition was observed in PES-
treated lesions (9).
Although this study did not intend to investigate the
impact of stent strut-related findings on clinical outcome, it
is noteworthy that 2 patients with a high density of both
protruding and malapposed struts as documented 5 years
after DES implantation developed late ST 6 months (SES
#7) and 1 year (SES #40) (Fig. 3C) after completion of this
OCT investigation. Table 6 summarizes the findings in
oth patients at baseline, follow-up, and at the time of the
ery late ST. An OCT cross section of the first patient
SES #40) obtained at 5 years is shown in Figure 4, where
xcessive coronary evaginations are noted (no OCT avail-
ble at the time of very late ST), whereas serial OCT
ndings (at 5 years and the time of very late ST) are shown
n Figure 7 for lesion SES #7. The 2 cases illustrate that
CT may play a role in identifying patients at risk for
uture adverse ischemic events. With respect to patho-
echanisms leading to very late ST, the 2 cases provide
vidence that very late ST beyond 5 years after DES
mplantation is not solely related to neoatheroslerosis and
ate restenosis, as both findings were not present.
Coronary evaginations. Coronary evaginations reflect a dis-
inct vessel wall morphology, which is characterized by an
utward bulging of the lumen between stent struts
pouches) (Fig. 4). In case of 1 evagination per cross
ection, the involved stent struts may appear as protruding.
hereas the phenomenon has been reported in case reports,
o single study has described the incidence and underlying
echanism to date. Histological evaluations of coronary
vaginations have not been reported so far, which may be
elated to the fact that the outward ballooning is more
pparent in vivo in a pressurized vessel than after histolog-
cal processing. We describe, for the first time, systemati-
ally the incidence and the extent of this OCT finding and
how that coronary evaginations are more common in SES-
han PES-treated lesions but with similar cross-sectional
reas and depth. The clinical significance of coronary evagi-
ations remains unclear. Hypothetically, coronary evaginations
ay represent an early stage of positive remodeling. Advanced
oronary evaginations may appear angiographically as peristent
ontrast staining, an entity that has been recently correlated
ith late adverse clinical outcome (21).
Study limitations. The presented data have to be interpreted
n light of several limitations. First, the data were obtained
n a highly selected patient population of event-free indi-
iduals 5 years after DES implantation. Second, the present
tudy provides OCT findings only at 5 years without a Taseline examination. This has implications regarding the
nalysis of malapposed struts as it cannot be excluded that
ifferences in malapposed struts were already present at
aseline (persistent rather than late acquired). However,
ntravascular ultrasound studies have shown that an impor-
ant proportion of malapposed struts at follow-up is related to
cquired rather than persistent malapposed struts (22). The
ynamic changes in the interaction of stent struts with the
rterial wall remain hypothetical and will require confirmation
n prospectively designed, serial OCT investigations. As it
elates to both strut protrusion and coronary evaginations,
atched histological evaluations are not available; therefore,
areful interpretations of these OCT findings are required.
Figure 7. Paired OCT Investigation at 5 Years (Routine per Protocol)
and 5.5 Years (at the Time of Very Late ST)
The serial cross sections in A1 to A4 show protruding struts with coronary
evaginations of the vessel wall (A1) and malapposition in subsequent
frames (A2 to A4). The vicinity of protrusion and malapposition suggests
that coronary evaginations with protruding struts may precede a detach-
ment of the vessel wall from the stent struts, leaving behind the visual
appearance of (late acquired) malapposed struts (A2 to A4). The potential
clinical relevance of these ﬁndings by optical coherence tomography (OCT)
are supported by the occurrence of a very late stent thrombosis (ST) 6
months after the 5-year OCT investigation (B1 to B4). In B1 to B4, the
zones of malapposition are ﬁlled with material suggestive of thrombus.he clinical impact of protruding struts and coronary
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957evaginations is not known and requires further evaluation in
prospective studies.
Conclusions
Early-generation DES show a similar degree of strut cov-
erage and malapposition at 5-year follow-up. Despite over-
all low rates of uncovered, malapposed, and protruding
struts, some lesions show a clustering of these characteris-
tics, indicating a heterogeneous healing pattern among
patients treated with early-generation DES. Two very late
ST cases in patients with a high number of malapposed or
protruding struts illustrate that OCT may play a role in
identifying patients at risk for future adverse ischemic
events.
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